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The Effects of KW-3902,
an Adenosine A1-Receptor Antagonist,
on Diuresis and Renal Function in Patients
With Acute Decompensated Heart Failure
and Renal Impairment or Diuretic Resistance
Michael M. Givertz, MD, FACC,* Barry M. Massie, MD, FACC,† Tara K. Fields, BA,‡
Leeanne L. Pearson, RN, BS,‡ Howard C. Dittrich, MD, FACC,‡§ on behalf of the CKI-201
and CKI-202 Investigators
Boston, Massachusetts; and San Francisco and San Diego, California
Objectives This study sought to evaluate the dose-dependent effects of adenosine A1-receptor blockade on diuresis and renal
function in patients with acute decompensated heart failure (ADHF) and renal impairment or diuretic resistance.
Background Intravenous loop diuretics are the mainstay of therapy for patients with ADHF. Treatment, however, may be com-
plicated by diuretic resistance and/or worsening renal function.
Methods We carried out a pair of randomized, double-blind, placebo-controlled, proof-of-concept studies in 2 clinically
challenging ADHF populations.
Results In the ADHF protocol, 146 patients with volume overload and an estimated creatinine clearance (CrCl) of 20 to
80 ml/min were randomized to placebo or 1 of 4 doses of KW-3902 (rolofylline) infused over 2 h daily for up to
3 days. On day 1, KW-3902 monotherapy increased urine output during the first 6 h (445, 531, 631, and 570
ml in the 2.5-, 15-, 30-, and 60-mg groups, respectively) compared with placebo (374 ml; p  0.02). On day 2,
serum creatinine decreased in all KW-3902 groups and increased with placebo (p  0.04). By day 4 or day of
discharge if earlier, intravenous furosemide administration tended to be lower in the KW-3902 groups compared
with placebo (p  0.10). In the diuretic-resistant protocol, 35 patients with an average CrCl of 34 ml/min were
randomized to a single infusion of placebo, 10, 30, or 60 mg of KW-3902. Compared with placebo, KW-3902
increased hourly urine volume and estimated CrCl with peak effects occurring at 2 to 3 h and at 24 h, respec-
tively. Adverse events were not different between placebo and KW-3902.
Conclusions In patients with ADHF and volume overload, KW-3902, an adenosine A1-receptor antagonist, enhances the
response to loop diuretics and may have a renal protective effect. (J Am Coll Cardiol 2007;50:1551–60)
© 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.07.019a
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teart failure is responsible for a large and still growing
roportion of cardiovascular morbidity and mortality. It is
he leading cause of hospitalization in patients over the age
f 65 years, with a large attendant cost. Most patients with
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ccepted July 11, 2007.cute decompensated heart failure (ADHF) are admitted
ith volume overload, and at least one-third have moderate
r severe baseline renal impairment (1). Practice guidelines
ecommend that ADHF patients with evidence of volume
verload be treated with escalating doses of diuretics (2),
lthough it is recognized that such therapy can be associated
ith worsening renal function. An increase in serum creatinine
SCr), whether linked to diuretic use or not, is associated with
ncreased risk of adverse short-term and long-term morbidity
nd mortality (3). Preservation of renal function, on the other
and, has been associated with improved prognosis (4).
Loop diuretics may adversely affect renal function
hrough tubuloglomerular feedback within the medulla
f the nephron. Increased concentrations of Na and Cl
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local generation of adenosine (5).
Adenosine then acts on specific
receptors in the nephron, with
the predominant A1-mediated
effect being constriction of the
afferent arteriole resulting in re-
ductions in renal blood flow and
glomerular filtration rate (GFR).
This, in turn, reduces delivery of
filterable ions to the distal
nephron (6). In addition, adeno-
sine has direct luminal effects,
enhancing sodium reabsorption
in the proximal tubule. In the
setting of heart failure, as GFR
eclines, higher doses of diuretics are required to effect
atriuresis and diuresis. Normally adaptive paracrine mech-
nisms at the juxtaglomerular apparatus are further stimu-
ated, leading to additional reductions in renal blood blow
nd GFR. Thus, adenosine A1-receptor antagonists may be
seful in the treatment of ADHF by inhibiting proximal
ubular reabsorption and tubuloglomerular feedback.
KW-3902 (rolofylline) is a novel, specific adenosine
1-receptor antagonist shown in animal models to cause
iuresis and natriuresis (7), in large part by inhibiting
odium reabsorption at tubular sites. Additional experimen-
al studies show that KW-3902 attenuates renal injury by
mproving renal blood flow (8). In phase I trials in normal
ubjects, intravenous (IV) doses of KW-3902 2.5 mg
roduced a significant natriuretic effect with a half-life of
pproximately 12 to 14 h and an acceptable safety profile
9). We sought to test the hypothesis that adenosine
1-receptor blockade improves the response to diuretics
nd preserves renal function in patients with ADHF. Two
linically challenging patient populations were studied in
andomized, double-blind, placebo controlled, proof-of-
oncept protocols: patients with ADHF with accompanying
enal impairment (ADHF protocol) and patients who were
iuretic refractory or resistant (diuretic-resistant protocol).
e report the results of both protocols.
ethods
DHF protocol. This was a randomized, double-blind,
lacebo-controlled, parallel-group study conducted at 44
ites in the U.S. The principal objectives were to determine
he optimal dose range of IV KW-3902 given initially as
onotherapy and subsequently in combination with IV
urosemide in improving urine output in heart failure
atients with renal impairment who required hospitalization
or fluid overload. Secondary objectives were to assess the
ffects of each dose of KW-3902 on renal function and
afety. Eligible patients were at least 18 years of age with
Abbreviations
and Acronyms
ADHF  acute
decompensated heart
failure
CrCl  creatinine clearance
GFR  glomerular filtration
rate
IV  intravenous
NYHA  New York Heart
Association
SBP  systolic blood
pressure
SCr  serum creatinineew York Heart Association (NYHA) functional class II to V heart failure and renal impairment defined as an esti-
ated creatinine clearance (CrCl) between 20 and 80
l/min using the Cockcroft-Gault equation (10). There was
o ejection fraction criterion for inclusion. Patients were
ospitalized with at least 2 of the following signs or symptoms
f fluid overload: jugular venous distension, pitting sacral or
edal edema, dyspnea, or documented weight gain.
Exclusion criteria included acute myocardial infarction
ithin 30 days; clinical evidence of ongoing ischemia
ausing worsening heart failure; uncorrected primary valvu-
ar, restrictive, or hypertrophic cardiomyopathy or pericar-
ial disease; implantation of a cardioverter-defibrillator or
ardiac resynchronization device within 7 days; need for
echanical ventilation, dialysis or ultrafiltration; active pul-
onary, vascular, renal, hepatic, cerebrovascular or systemic
isease; or a recent surgical or diagnostic procedure that
ould confound heart failure management or interpretation
f study results. Pregnant or breastfeeding women were
xcluded, as were patients with a serum potassium level
3.0 mEq/l or systolic blood pressure (SBP) 85 mm Hg.
The primary efficacy end point was total urine output
uring the 6 h after the first dose of KW-3902 or placebo.
econdary efficacy end points included change in urine flow
ate over the first 6 h, change in SCr level at day 4 (or early
ermination), proportion of patients with worsening renal
unction at day 4/early termination, defined as an increase
rom baseline in SCr 0.3 mg/dl, mean cumulative dose of
V furosemide, and number of subjects withdrawn from the
tudy because of treatment failure, defined as requirement
or further treatment after all protocol-specified increases in
iuretic therapy were administered. Adverse events were
onitored during and after the treatment period up to 30
ays.
Eligible patients were enrolled within 48 h (days 2
o 1) before the first dose of study drug (Fig. 1A). After
ritten informed consent, patients were randomized to
eceive placebo or 1 of 4 doses of KW-3902 (2.5, 15, 30, or
0 mg). All patients received 40 mg IV furosemide on the
vening of day 1, 12 h before the first dose of study drug.
ubjects who were no longer fluid overloaded after the 40
g dose or for whom this dose was clinically insufficient (and
hus required prompt, additional diuretic therapy) were with-
rawn from the study before the first dose of study drug.
atients were maintained on a 2-g sodium diet throughout the
tudy period.
On day 1, a single dose of KW-3902 or placebo was
dministered in a blinded fashion as a 2-h IV infusion at a
ate of 1 ml/min. Administration of loop diuretic was
rohibited for 6 h after the initiation of study drug. An
nvestigator-defined need for additional diuretic therapy
uring the course of the infusion was considered a treatment
ailure and precipitated patient withdrawal. After 6 h,
ubjects could receive furosemide as clinically indicated by
he investigator or treating physician. Use of oral diuretics,
xcept aldosterone antagonists, was prohibited from the
12 h time point through 6 h after study drug infusion.
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October 16, 2007:1551–60 Adenosine Receptor Blockade in ADHFetolazone could subsequently be added if the investigator
udged it medically necessary. On days 2 and 3, study drug
as administered as a 2-h infusion at approximately the
ame time as on day 1; IV furosemide could be given at any
ime at the investigator’s discretion.
Continuous urine collection, recording of fluid intake,
nd Holter monitoring were performed beginning with the
dministration of IV furosemide on day 1. Vital signs,
igns and symptoms of heart failure, and laboratory values
ere determined before each study drug infusion and on day
or day of discharge, whichever came first. Patients were
ithdrawn from the study if they required mechanical
entilation, ultrafiltration, hemodialysis, IV vasodilators, or
ositive inotropic support; if treatment was successful before
ay 4, or if they experienced a serious adverse event.
ubjects were contacted by telephone at 30 days to assess
eneral status and serious adverse events.
iuretic-resistant protocol. This was a randomized,
ouble-blind, placebo-controlled, dose-escalation study
onducted at 11 sites in the U. S. The principal objectives
ere to compare 3 doses of KW-3902 and placebo with
easures of their effects on urine volume and CrCl, and to
ssess safety. Eligible patients had NYHA functional class
II or IV heart failure and were currently hospitalized and
eceiving diuretic therapy (and, if necessary in the view of
he treating physician, IV inotropic or vasodilator therapy).
n the opinion of the investigators, the patients had to have
eached the point where a further increase in diuretic
herapy was unlikely to be effective or would worsen renal
unction and where the investigator was considering more
ggressive management of fluid overload, including the use
f further IV vasoactive medications, mechanical circulatory
upport, ultrafiltration, or dialysis. Examples of diuretic
efractoriness included: the combination of 160 mg IV
urosemide plus 5 mg oral metolazone given 1 or more times
n a day, or an infusion of furosemide at more than 20 mg/h
hat does not yield any significant increase in urine output or
eduction in edema, weight, or fluid volume status. Other
nclusion/exclusion criteria were similar to the ADHF
rotocol with the exception that there was no requirement
or CrCl to fall within a defined range.
The primary efficacy end point was the change in hourly
rine output at intervals over a 24-h period after adminis-
ration of KW-3902 or placebo, with the average hourly
rine output from 3 to 0 h serving as a baseline. The
rincipal secondary end point was the change in CrCl from
aseline at 3, 6, 9, 12, and 24 h after dosing. Additional
fficacy end points included other measures of cumulative and
ourly urine output, use of additional IV furosemide after study
rug administration, and use of IV vasoactive agents, ultrafil-
ration, and mechanical ventilation. Change in heart failure
igns and symptoms, and adverse events were also recorded.
Hospitalized subjects who met entry criteria and provided
ritten informed consent were randomized 2:1 to receive a
ingle dose of KW-3902 (10, 30, or 60 mg) or placebo
dministered as a 2-h IV infusion (Fig. 1B). Current 6iuretic therapy was discontinued at least 5 h before
dministration of study drug to allow baseline urine volume
nd CrCl to be measured for the 3-h period before study
rug administration. After study drug infusion, IV diuretics
ere administered at the investigator’s discretion. Urine
olume was measured hourly between 1 and 12 h and at
4 h after study drug infusion. CrCl was measured at 3-h
ntervals up to 12 h, and between 12 and 24 h. Fluid intake
as measured continuously.
tatistical analysis. Data from all subjects treated with at
east 1 dose of study drug were included in the analyses.
afety data were summarized with descriptive statistics and
re presented for the combined study populations. Data are
resented as mean  standard deviation (unless otherwise
oted). All statistical analyses were performed using SAS
ersion 8.2 or higher (SAS Institute Inc., Cary, North
arolina). A result was considered statistically significant
hen the associated 2-sided statistical test yielded a p value
f 0.05 or less. No p value adjustment was made for multiple
omparisons because these were dose-ranging pilot studies.
DHF PROTOCOL. Sample size (for the primary end point)
as calculated using the assumption that the observed
ifference would be 400 ml with a standard deviation of 500
l. At 80% power, this yielded 26 patients per treatment
roup. For the primary efficacy end point, mean cumulative
rine volume in the first 6 h aftere initial infusion of study
rug, as well as the secondary end points of change in SCr
rom baseline and mean daily cumulative dose of IV
urosemide, data were summarized and treatment groups
ere compared using a one-way analysis of variance model
ith factor treatment. Normality (Shapiro-Wilk) and ho-
ogeneity of variances (Bartlett) were tested before analysis,
nd the distributions of these variables were found to be
ignificantly non-normal and/or were not valid for the
ssumption of homogeneity of variance. Therefore, the rank
ransformation was performed and data were analyzed using
nonparametric analysis of variance (analysis of covariance).
or change in SCr, SCr at baseline was used as the
ovariate. The proportion of subjects with an increase in
Cr 0.3 mg/dl from baseline or with a reduction in or
iscontinuation of diuretics because of worsening renal
unction during the treatment period were determined by
ichotomizing data into binary responses (outcome present
r not present) and then performing a pairwise comparison
or each time point and overall for each dose to placebo
sing the Fisher exact test.
IURETIC-RESISTANT PROTOCOL. This study was explor-
tory, and not powered for statistical significance. All data
ere summarized using descriptive statistics.
esults
DHF protocol. A total of 159 subjects were randomized.
hirteen subjects did not receive study drug (4 randomized
o placebo, 3 to 2.5 mg, 1 to 15 mg, 2 to 30 mg, and 3 to
0 mg KW-3902) because they were not volume overloaded
o
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Adenosine Receptor Blockade in ADHF October 16, 2007:1551–60r had required rescue therapy, including supplemental
urosemide, during the 12-h baseline period. Thus, a total of
46 subjects were treated with at least 1 dose of study drug.
emographic and baseline characteristics were similar
cross treatment groups (Table 1). The study population
as older and predominantly male (69%), and approxi-
ately one-half had heart failure of ischemic etiology. Mean
jection fraction ranged from 26% to 37% across study
roups. At baseline, patients had at least moderate renal
mpairment with mean SCr and CrCl of 1.8 mg/dl and 48
l/min, respectively.
RINE OUTPUT IN FIRST 6 H. In all dose groups, KW-3902
onotherapy resulted in higher cumulative urine output
uring the first 6 h compared with placebo (Fig. 2). This
ifference was statistically significant for the 30-mg group
631  506 ml vs. 374  190 ml, p  0.02). By 24 h,
umulative urine volumes were similar for all treatment
roups. Between 1 h and 2 h after initiation of infusion,
tatistically significant, transient increases in urine flow rate
elative to baseline were observed for the 30- and 60-mg
W-3902 groups (from 123  60 ml/h to 139  149 ml/h
p  0.02] and 124  111 ml/h to 133  149 ml/h [p 
.03], respectively). From baseline to 6 h, there were no
ignificant differences in the change in SBP or heart rate
mong the 5 treatment groups (6.1  14 mm Hg, 2.1 
6 mm Hg, 2.6  14 mm Hg, 6.6  14 mm Hg, and
Figure 1 Flow Diagrams Depicting Study Protocols
(A) Acute decompensated heart failure (ADHF) patients with renal impairment.
(B) ADHF patients who were resistant or refractory to diuretics. CrCl  creatinine3.8  18 mm Hg and 2.8  7 beats/min, 1.0  8 Aeats/min, 0.9  12 beats/min, 0.3  9 beats/min, and
0.8  12 beats/min in the placebo and KW-3902 2.5-,
5-, 30-, and 60-mg groups, respectively).
ISCONTINUATION OF TREATMENT. Treatment was discon-
inued before day 3 in 64 subjects (44%). The primary
eason for early discontinuation was adequate diuresis,
bserved most frequently in the 3 highest KW-3902 dose
roups (30% to 39% of subjects) (Table 2). Early discon-
inuation of treatment because of adequate diuresis was
eported for 1 subject (4%) in the placebo group. Few
ubjects (6% overall) had discontinued treatment because of
reatment failure. Other reasons for early discontinuation
ncluded adverse events (2 subjects in the placebo group; 1
ach in the 2.5- and 60-mg KW-3902 groups), death (1
ubject in the 60-mg group), investigator discretion (2
ubjects in the placebo group; 1 each in the 2.5-, 15-, and
0-mg KW-3902 groups), and subject request (1 in the
.5-mg and 3 in the 15-mg KW-3902 groups).
HANGE IN SERUM CREATININE. On Day 2 of therapy, SCr
ad decreased in all KW-3902 groups relative to baseline
0.08, 0.03, 0.06, and 0.03 mg/dl for the 2.5-, 15-,
0-, and 60-mg groups, respectively), whereas placebo
ubjects had a mean increase in SCr of 0.04 mg/dl (p 
.04 for 30 mg KW-3902 vs. placebo). With the exception
f the 60-mg KW-3902 group, all treatment groups had
ecreased SCr levels on Day 4 or the day of discharge.
ce; IV  intravenous.clearanlthough not significantly different, larger mean decreases
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October 16, 2007:1551–60 Adenosine Receptor Blockade in ADHFn SCr were observed for subjects in the 2.5-, 15-, and
0-mg KW-3902 groups (0.07,0.04, and0.09 mg/dl,
espectively) compared with placebo (0.01 mg/dl). For
ubjects who received 60 mg KW-3902, SCr was increased
elative to baseline (0.03 mg/dl). By day 4/day of dis-
Placebo 2.5 mg 15 mg 30 mg 60 mg
0
200
400
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Figure 2 Urine Output in First 6 h
Cumulative urine volume (mean  SEM) 6 h after initiation of placebo or
KW-3902 in acute decompensated heart failure patients with renal impairment
(*p  0.02 vs. placebo).
DHF Protocol Baseline Characteristics
Table 1 ADHF Protocol Baseline Characteristics
Placebo (n  27) 2.5 mg (n 
Age, yrs 67 14 64 14
Male, % 74 66
Race/ethnicity, n (%)
Caucasian or Hispanic 19 (70) 24 (83)
Black 7 (26) 5 (17)
Other 1 (4) 0 (0)
NYHA functional class, n (%)
III 14 (52) 12 (41)
IV 12 (44) 17 (59)
LVEF, % (n) 34 18 (20) 37 17 (1
Weight, kg 92 19 103 29
HF etiology, n (%)
Ischemic 15 (56) 11 (38)
Idiopathic 5 (19) 6 (21)
Hypertensive 1 (4) 3 (10)
Medications, n (%)
ACE inhibitor/ARB 24 (89) 25 (86)
Beta-blocker 21 (78) 26 (90)
Digoxin 15 (56) 12 (41)
Aldosterone inhibitor 0 (0) 0 (0)
HR, beats/min 80 16 77 13
SBP, mm Hg 121 23 124 22
Serum Cr, mg/dl 1.9 0.6 1.6 0.8
CrCl, ml/min 41 22 47 27
CE angiotensin-converting enzyme; ADHF  acute decompensated heart failure; ARB  angiot
VEF  left ventricular ejection fraction; NYHA  New York Heart Association; SBP  systolic blosharge, the percentages of subjects with worsening renal
unction (defined as an increase in SCr  0.3 mg/dl) were
ot significantly different between the treatment groups:
%, 3%, 7%, and 17% in the 2.5-, 15-, 30-, and 60-mg
W-3902 groups, respectively, compared with 19% in the
lacebo group.
IURETIC ADMINISTRATION. Daily furosemide administra-
ion tended to be lower for the 3 highest doses of KW-3902
Fig. 3). The difference between the 30-mg dose of KW-
902 and placebo was statistically significant on day 2 (p 
.05). Cumulative IV furosemide administration through
ay 4/day of discharge was lower in all KW-3902 dose
roups (353  67 mg, 256  39 mg, 223  26 mg, and
15  30 mg for 2.5-, 15-, 30-, and 60-mg groups,
espectively) compared with placebo (393  73 mg) (p 
.0997 by Kruskal-Wallis test). Daily urine volume for the
rst 3 days and total urine volume and body weight at day
/day of discharge were not significantly different among
he 5 treatment groups (data not shown).
iuretic-resistant protocol. A total of 35 subjects were
andomized, and all were treated with study drug (Table 3).
ne subject in the placebo group discontinued treatment
ecause of transient hypotension after study drug infusion.
here were differences among treatment groups in demo-
raphic and baseline characteristics, presumably because of
KW-3902
15 mg (n  31) 30 mg (n  30) 60 mg (n  29)
69 12 66 15 67 13
65 70 69
22 (71) 22 (73) 23 (79)
9 (29) 8 (27) 5 (17)
0 (0) 0 (0) 1 (3)
18 (58) 14 (47) 15 (52)
13 (42) 15 (50) 12 (41)
28 12 (18) 34 16 (23) 26 15 (22)
87 29 97 24 92 32
18 (58) 15 (50) 15 (54)
4 (13) 2 (7) 3 (11)
3 (10) 4 (13) 5 (18)
29 (94) 19 (63) 27 (93)
26 (84) 23 (77) 25 (86)
10 (32) 10 (33) 16 (55)
0 (0) 2 (7) 0 (0)
77 14 81 13 76 16
122 19 131 22 121 26
1.8 0.7 1.7 0.6 1.8 0.7
42 22 59 55 49 36
ceptor blocker; Cr  creatinine; CrCl  creatinine clearance; HF  heart failure; HR  heart rate;
sure.29)
7)mall subject numbers. The baseline SCr level ranged from
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Adenosine Receptor Blockade in ADHF October 16, 2007:1551–60.9 0.4 mg/dl in the 60-mg KW-3902 group to 2.6 0.7
g/dl in the 15-mg KW-3902 group, and the calculated
rCl ranged from 30  15 ml/min in the 30-mg group to
1  22 ml/min in the placebo group. For the entire
opulation, concomitant medications included renin-
ngiotensin system inhibitors in 37%, beta-blockers in 60%,
nd digoxin in 34%. Use of parenteral vasoactive agents was
ommon, including milrinone (23%), nesiritide (23%), do-
utamine (17%), and dopamine (11%).
HANGE IN URINE OUTPUT. Overall, subjects treated with
lacebo had decreased hourly urine output relative to baseline
hrough 24 h (Fig. 4). By contrast, increased urine output
as observed for all KW-3902 dose groups within the first
h after study drug administration, with the peak effect
ccurring at 2 h to 3 h in the 30-mg dose group. This early
ffect on urine output was associated with increased sodium
xcretion (Table 4). By 5 h to 6 h, there was no difference
mong KW-3902 groups, and thereafter, there was no
onsistent pattern of increases or decreases from baseline in
ny KW-3902 group. The absolute change in urine flow
ate at 6 h compared with baseline was positive in all
W-3902 groups, ranging from 22 ml/h to 24 ml/h,
Figure 3 Daily Administration of IV Diuretics
Daily dose of intravenous (IV) furosemide (mean  SEM) administered to the
placebo and 4 KW-3902 groups over the first 3 days of the study (*p  0.05
vs. placebo).
ADHF Protocol Patient Disposition
Table 2 ADHF Protocol Patient Disposition
Placebo
(n  27
Disposition, n (%)
Completed treatment 20 (74)
Prematurely discontinued 7 (26)
Reason for premature discontinuation, n (%)
Adequate diuresis 1 (4)
Treatment failure 1 (4)
Adverse event 2 (7)
Death 0 (0)
Other 3 (11)
ADHF  acute decompensated heart failure.lhereas subjects treated with placebo had a decrease in
rine flow rate of 29 ml/h (Fig. 5). Administration of loop
iuretics within the first 4 h after start of study drug was
imilar between treatment groups (7 of 12, 7 of 8, 4 of 8, and
of 7 for placebo, 10-, 30-, and 60-mg KW-3902,
espectively).
HANGE IN CRCL. We assessed the absolute change from
aseline in CrCl during 3-h time intervals. For each 3-h
nterval, mean CrCl in the KW-3902 30-mg group in-
reased compared with baseline (Fig. 6). Conversely, the
ean CrCl for placebo decreased compared with baseline at
ll time intervals. Notably, CrCl at 24 h was substantially
ncreased compared with baseline for both 10- and 30-mg
W-3902 groups (25 and 65 ml/min, respectively; p 
.05 for 30 mg vs. baseline).
afety. ADHF PROTOCOL. Adverse events occurred in 85%
f placebo-treated patients and from 73% to 87% of
W-3902–treated patients. Serious adverse events through
0 days were reported for 54 subjects (37%) (Table 5).
ardiac disorders were the most commonly reported, and
lthough more frequent among subjects treated with
W-3902, the incidence was not dose-related or signif-
cantly different compared with placebo. The most com-
on cardiac event was acute exacerbation of heart failure.
n 14 of 24 cases (58%), this occurred 2 to 4 weeks after
tudy drug discontinuation. Acute respiratory distress and
simple partial seizure were reported for a single subject
n the 60-mg KW-3902 group. Among patients with
erious adverse events leading to premature discontinua-
ion of study drug, 2 occurred in placebo patients, 2 each
n the 2.5- and 60-mg KW-3902 groups, 3 in the 15-mg
W-3902 group, and 0 in the 30-mg KW-3902 group.
There were a total of 10 deaths reported during the study
eriod from initiation of study drug to 30 days. An
dditional 2 patients died after completing the 30-day
ollow-up. Of these 12 deaths, 1 occurred in the placebo
roup and 11 were distributed among the 4 KW-3902
roups. All but 1 event in the KW-3902 group occurred at
KW-3902
2.5 mg
(n  29)
15 mg
(n  31)
30 mg
(n  30)
60 mg
(n  29)
21 (72) 13 (42) 15 (50) 13 (45)
8 (28) 18 (58) 15 (50) 16 (55)
4 (14) 12 (39) 9 (30) 11 (38)
0 (0) 2 (7) 3 (10) 2 (7)
1 (3) 0 (0) 0 (0) 1 (3)
0 (0) 0 (0) 0 (0) 1 (3)
3 (10) 4 (13) 3 (10) 1 (3))east 13 days after the last dose of study drug. In the single
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eath was superior mesenteric artery occlusion related to
nderlying vascular disease.
IURETIC-RESISTANT PROTOCOL. There were no differ-
nces among groups in adverse events. There were no
linically significant differences in mean laboratory values or
requency of outliers for laboratory or Holter data. Serious
dverse events were reported for 5 subjects (9%): 2 in the
lacebo group, and 1 and 2 in the 30- and 60-mg KW-3902
roups, respectively.
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Figure 4 Change in Urine Output over 24 h
Change in hourly urine volume (mean  SEM) through 24 h after dosing with
placebo or KW-3902 in acute decompensated heart failure patients refractory/
resistant to diuretics.
Diuretic-Resistant Protocol Baseline Characteris
Table 3 Diuretic-Resistant Protocol Baseline
Placebo (n  12)
Age, yrs 68 16
Male, % 67
Race/ethnicity, n (%)
Caucasian or Hispanic 10 (83)
Black 2 (17)
NYHA functional class, n (%)
III 7 (58)
IV 5 (42)
Weight, kg 105 31
HF etiology, n (%)
Ischemic 9 (75)
Idiopathic 2 (17)
IV medications, n (%)
Vasodilators 1 (8)
Positive inotropes 4 (33)
HR, beats/min 75 12
SBP, mm Hg 114 23
Serum Cr, mg/dl 2.4 1.0
CrCl, ml/min 41 22
IV  intravenous; other abbreviations as in Table 1.iscussion
n these proof-of-concept studies, we sought to determine
he effects of adenosine A1-receptor blockade on diuresis
nd renal function in patients with ADHF and renal
mpairment or diuretic resistance. In the ADHF protocol,
W-3902 at all 4 doses was associated with increases in
rine output during the 6-h period after the first dose.
W-3902 also seemed to have a similar effect on urine
utput over at least 6 h in a sicker group of patients enrolled
n the diuretic-resistant protocol. Importantly, enhanced
iuresis with KW-3902 was associated with the use of lower
oses of loop diuretics. In the larger ADHF protocol, which
llowed for up to 3 days of study drug dosing, early discontin-
ation of IV loop diuretics as a result of investigator-classified
uccessful diuresis occurred in a substantially greater propor-
ion of KW-3902–treated patients (30%) than placebo-
reated patients (4%).
Plasma adenosine levels are elevated in patients with
eart failure (11), and adenosine A1 receptors in the kidney
ediate vasoconstriction of afferent arterioles, reabsorption
f sodium and water in proximal tubules, and tubuloglo-
erular feedback in the juxtaglomerular apparatus (6).
racteristics
KW-3902
mg (n  8) 30 mg (n  8) 60 mg (n  7)
66 14 63 12 72 10
63 25 71
4 (50) 5 (63) 7 (100)
4 (50) 3 (38) 0 (0)
2 (25) 5 (63) 2 (29)
6 (75) 3 (38) 5 (71)
09 29 91 17 95 21
4 (50) 2 (25) 6 (86)
2 (25) 4 (50) 1 (14)
4 (50) 1 (13) 2 (29)
5 (63) 5 (63) 4 (57)
77 12 81 14 76 10
07 17 113 27 109 18
2.6 0.7 2.2 0.7 1.9 0.4
31 12 30 15 35 15
rinary Sodium ConcentrationsmEq/l) in the Diuretic-Resistant Protocol
Table 4 Urinary Sodium Concentrations(mEq/l) in the Diuretic-Resistant Protocol
KW-3902
Placebo 10 mg 30 mg 60 mg
Baseline 67 32 63 37 62 49 42 37
Hour 3 72 28 64 41 80 33 49 25tics
Cha
10
1
1Change, baseline to hour 3 6 13 10 16 18 22 4 31
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ected to increase renal blood flow and enhance diuresis.
he effects of KW-3902 on renal function are consistent
ith those obtained with another adenosine A1-receptor
ntagonist in both experimental (12) and human (13) heart
ailure. In a pacing-induced model of heart failure, BG9719
ncreased urine flow and sodium excretion 6- to 10-fold,
hile exerting a beneficial effect on CrCl (12). Gottlieb
t al. (13) studied patients with chronic heart failure and
ound that although furosemide and the adenosine A1-
eceptor antagonist each produced diuresis when given
lone, furosemide monotherapy was associated with a de-
line in CrCl. The 2 lower doses of adenosine A1-receptor
ntagonist as monotherapy improved CrCl, and when given
oncomitantly with furosemide, enhanced diuresis and
lunted the decline in CrCl observed with the loop diuretic
lone.
In the ADHF protocol, although furosemide require-
ents were lower in the 60-mg KW-3902 group at day
/day of discharge, the percentage of patients in this group
ith worsening renal function approximated that seen in the
lacebo group. Similarly, in the diuretic-resistant protocol,
lthough CrCl improved in both the 10- and 30-mg
W-3902 groups, it seemed to deteriorate in the 60-mg
roup. Taken together, these findings suggest that a dose of
5 mg or 30 mg is appropriate for further investigation in a
hase III study. Furthermore, the suggestion of a descend-
ng limb of the KW-3902 dose response with regard to renal
unction is compatible with effects observed with the highest
ose of BG9719 (13). This phenomenon might reflect the
ultiple actions of adenosine in the kidney, acting through
t least 4 classes of receptor (A1, A2a, A2b, and A3) (6). It
annot be excluded that KW-3092 at higher doses acts at
ther receptors (with a resulting countervailing effect on
enal function) or that greater degrees of specific A1-
eceptor antagonism are responsible for a worsening of renal
unction. In addition, adenosine receptors are ubiquitous
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Figure 5 Change in Urine Flow Rate at 6 h
Change in urine flow rate (mean  SEM) between 5 h and 6 h
after administration of placebo or KW-3902 compared with baseline.nd adenosine has effects on multiple organs. Based on theata available from these studies, it is impossible to exclude
n extrarenal mechanism for some of these findings, al-
hough preclinical studies of adenosine A1-receptor antag-
nists have not indicated such a mechanism (12). In both
he ADHF and diuretic-resistant protocols, KW-3902 had
o effect on heart rate or blood pressure; lack of systemic
ffects also was observed with BG9719 in patients with
hronic heart failure (13).
linical implications. Renal function is a strong, indepen-
ent predictor of short-term and long-term prognosis in
atients with heart failure, and acute worsening of renal
unction predicts poor outcomes, regardless of baseline renal
unction. Approximately 70% of hospitalized patients with
eart failure experience an increase in serum creatinine of at
east 0.1 mg/dl and up to 45% experience an increase of
0.3 mg/dl (14,15). Regardless of the definition used,
orsening renal function has been associated with longer
engths of stay, more complications, higher in-hospital
ortality, and higher post-discharge rates of death and
eadmission (3,16). Higher diuretic doses have been asso-
iated with more frequent and greater increases in serum
reatinine, and such changes often lead physicians to reduce
r withhold diuretic and other vasoactive therapy (e.g.,
enin-angiotensin system inhibitors), which may contribute
o worsening heart failure and prolongation of hospitaliza-
ion. Therefore, an agent that facilitates diuresis with lower
oses of loop diuretics or prevents worsening renal function
uring the management of volume overload could be very
seful in the treatment of patients with ADHF. Given the
ssociation between higher oral diuretic doses and adverse
utcomes in advanced heart failure (17), the role of chronic
denosine receptor blockade in the ambulatory setting also
eserves study.
afety. These protocols represent the largest experience to
ate of adenosine A1-receptor blockade in patients with
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Figure 6 Change in CrCl over 24 h
Change in measured creatinine clearance (CrCl) (mean  SEM) relative to
baseline in acute decompensated heart failure patients refractory/resistant to
diuretics (*p  0.05 vs. baseline).
h
e
s
w
t
r
c
b
t
a
c
a
c
c
t
n
i
a
c
a
p
b
e
b
w
s
r
3
o
t
o
s
d
s
S
l
s
o
o
r
s
t
t
r
e
d
a
r
t
p
t
t
I
3
p
f
d
d
v
e
f
d
t
f
q
C
T
h
e
t
a
t
o
l
a
t
e 60-m
1559JACC Vol. 50, No. 16, 2007 Givertz et al.
October 16, 2007:1551–60 Adenosine Receptor Blockade in ADHFeart failure and the first in vivo study in ADHF. Adverse
vents were reported in up to 40% of patients, reflecting the
everity of illness in the study population, but no differences
ere observed between KW-3902–treated and placebo-
reated patients. In preclinical studies, adenosine A1-
eceptor blockers have not been associated with adverse
ardiovascular or renal effects, and in the prior clinical study
y Gottlieb et al. (13), a single dose of BG9719 was well
olerated. However, adenosine receptors in the heart medi-
te a number of important physiologic effects, including
oronary vasodilation, atrioventricular nodal conduction,
nd anti-inflammatory effects, and inhibition of these re-
eptors carries theoretical risks (18,19). We observed no
hange in heart rate, heart rhythm, or blood pressure in
hese protocols, and there was no evidence of excess coro-
ary ischemic events.
Adenosine, acting at A1 receptors in the brain, is also an
nhibitory neuromodulator. Because levels of endogenous
denosine are elevated in the brain after seizure, it is
onsidered an endogenous anticonvulsant (20). Although
denosine A1-receptor blockade does not induce seizures in
reclinical studies, modulation of A1-receptor activity has
een shown to affect seizure activity in animal models of
pilepsy, with activation raising the seizure threshold and
lockade lowering it (21). In the ADHF protocol, 1 patient
ho received 60 mg KW-3902 experienced a simple partial
eizure. Immediately before the seizure, this patient expe-
ienced wide swings in serum glucose concentrations from
4 to 454 mg/dl, and on the preceding day had been started
n pseudoephedrine, a known proconvulsant. These observa-
ions suggest that KW-3902 might lower the seizure thresh-
ld. This could prove clinically significant in patients at risk of
eizure, and needs to be considered in the design and choice of
ose in future studies with KW-3902 and other agents that
hare the same mechanism of action.
tudy limitations. Phase II protocols are, by design, pre-
iminary in nature. Two primary goals of our study were to
how proof of concept with regard to the potential benefits
f adenosine A1-receptor blockade and to evaluate a range
ADHF Protocol Serious Adverse Events
Table 5 ADHF Protocol Serious Adverse Eve
Placebo
(n  27)
2.5
(n 
Subjects with 1 serious
adverse event
8 (30) 8
Cardiac 4 (15) 5
Renal 3 (11) 1
Metabolic 1 (4) 0
Respiratory 0 (0) 0
Vascular 0 (0) 1
Gastrointestinal 2 (7) 2
Other* 2 (7) 0
Values are expressed as n (%). *Includes 1 simple partial seizure in th
ADHF  acute decompensated heart failure.f doses of KW-3902 from which to further assess clinically Aelevant dose-response relationships and safety. They were
uccessful in providing important information concerning
hese objectives in 2 important groups of ADHF patients—
hose with coexisting renal dysfunction and those that fail to
espond adequately to usual approaches to diuresis. How-
ver, it is important to recognize the limitations of these
ata. Although it seems that adenosine A1-receptor block-
de is associated with enhanced diuresis, preservation of
enal function, and a perhaps lesser need for loop diuretics,
hese data were acquired in relatively small numbers of
atients at limited sites. Furthermore, dosing of concomi-
ant medications, including parenteral diuretics and vasoac-
ive agents, was at the discretion of the treating physician.
mportantly, we did not test the diuretic effects of KW-
902 against furosemide. In the case of the diuretic-resistant
rotocol, because of widely divergent treatment practices and
requent changes, diuretic type and dosing before the study
rug were not collected. Lastly, we cannot comment on the
ifferential effects of KW-3902 in heart failure with preserved
ersus reduced systolic function. These results do provide
vidence for greater effects with infusions of KW-3902 ranging
rom 2.5 to 30 mg and suggest that doses higher than 30 mg
o not offer incremental benefit, but they are insufficient in
hemselves to define an optimal dose, infusion duration, or
requency. Lastly, much greater patient exposure will be re-
uired to evaluate the safety of this agent.
onclusions
hese results indicate that adenosine A1-receptor blockade
as a potential role as an adjunct to loop diuretics to
nhance diuresis in the treatment of ADHF, both reducing
he amount of loop diuretic necessary to treat such patients
nd preventing deterioration of renal function during
reatment. Further trials will be required to determine the
ptimal approach to administering KW-3902 and estab-
ish its efficacy and safety in patients with ADHF and
ccompanying renal dysfunction. Two large-scale trials in
his population (PROTECT [A Study of the Selective
KW-3902
15 mg
(n  31)
30 mg
(n  30)
60 mg
(n  29)
15 (48) 8 (27) 15 (52)
9 (29) 6 (20) 7 (24)
2 (6) 0 (0) 4 (14)
3 (10) 0 (0) 0 (0)
2 (7) 0 (0) 3 (10)
1 (3) 2 (7) 0 (0)
3 (10) 0 (0) 1 (3)
1 (3) 1 (3) 3 (10)
g KW-3902 group.nts
mg
29)
(28)
(17)
(3)
(0)
(0)
(3)
(7)
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2) already have commenced, and an additional study will
arget hospitalized patients with more severe or worsening
enal dysfunction.
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